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Abstract
Objectives An ill-defined hyperintense edge and hypointense
core on diffusion-weighted imaging (DWI) is typical of pro-
gressive multifocal leukoencephalopathy (PML).We aimed to
investigate whether a b-value of 3,000 s/mm2 (b3000) can
improve visualisation of PML, or provide different structural
information compared to 1,000 s/mm2 (b1000).
Methods We retrospectively identified HIV-positive patients
with confirmed PML studied under a clinical protocol includ-
ing both b1000 and b3000 DWI. The rim and core of each
PML lesion and normal-appearing white matter (NAWM)
were outlined on trace-weighted DWI. Signal intensities, ap-
parent diffusion coefficient (ADC) values and volumes were
measured and compared between b1000 and b3000.
Results Nine lesions from seven patients were analysed. The
rim and core were better visualised on b3000, with higher
signal of the rim and lower signal of the core compared to
NAWM. The hyperintense rim had non-restricted average
ADCs, but included foci of low ADC on both b3000 and
b1000. Despite similar total lesion volumes, b3000 displayed
significantly larger core and smaller rim volumes than b1000.
Conclusion b3000 improves visualisation of this important
PML hallmark. Moreover, b3000 partly reclassifies tissue
from rim into core, and might provide potentially more accu-
rate biomarkers of PML activity and prognosis.
Key Points
• B3000 improves contrast resolution between lesion rim, core
and normal-appearing white matter.
• B3000 improves identification of the typical rim-and-core
pattern of PML lesions.
• B3000 and b1000 similarly identify lesions, but b3000 re-
sults in smaller rims and larger cores.
• B3000 excludes some high diffusion components from rim,
reclassifying them into core.
• B3000 DWI may provide more precise PML biomarkers of
disease activity and tissue damage.
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Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare,
potentially life-threatening demyelinating disease of the brain
white matter [1] caused by JC virus (JCV) [2, 3] in immuno-
compromised hosts.
PML is a typical complication of patients with HIV-
infection (HIV+) [4], but over the last decade has been
increasingly described in the setting of immunosuppres-
sive regimens, including natalizumab in patients with
multiple sclerosis (MS) [5–8].
An early diagnosis of PML is crucial to optimise clinical
management of patients (e.g. by potentiating combined anti-
retroviral therapy (cART) in HIV+ patients [9], or reducing
the intensity of iatrogenic immunosuppression) and to im-
prove long-term outcomes [10].
When typical pathological findings are present [11], histol-
ogy allows a definite diagnosis of PML. However, brain bi-
opsy has many drawbacks, including low sensitivity due to
sampling errors and possible complications from the invasive
procedure. Last but not least, it entails a previous clinical
suspicion of PML.
All these pitfalls highlight the importance of alternative and
less invasive diagnostic clues. Recently, the American
Academy of Neurology (AAN) Neuro-infectious Disease
Section reviewed the diagnostic criteria for PML and
established that PML diagnosis can be made with different
degrees of certainty (possible, probable and definite) upon a
combination of typical clinical imaging findings, and evidence
of JC virus in the cerebrospinal fluid (CSF) [11].
According to this consensus statement, imaging plays an
important role in suggesting or confirming PML diagnosis.
Compatible imaging findings are white matter lesions that
often start in the subcortical regions with involvement of the
U-fibres, and then move into the deeper white matter of the
centrum semiovale and eventually evolve into full blown,
largely confluent T2 hyperintense and T1 hypointense non-
enhancing lesions. Infratentorially the PML lesions typically
involve the middle cerebellar peduncles [12–14]. In the setting
of HIV infection, other conditions like HIV encephalopathy
can affect white matter and represent a diagnostic challenge
[12, 14, 15]. An increased MRI accuracy for PML would thus
be highly desirable in order to recognise PML lesions in case
of unspecific findings on T1- and T2-weighted images. This
may in the end reduce the necessity of brain biopsy or even of
a JCV-positive CSF for PML diagnosis.
Of note, PML lesions can show an ill-defined rim of
high signal intensity at the advancing edge and a
hypointense core on diffusion-weighted imaging (DWI)
[16–18]. This PML feature is peculiar and differs from
the DWI findings observed in other demyelinating and
non-demyelinating diseases [19–21]. Histological-
radiological comparisons demonstrated that DWI periph-
eral bright rim and hypointense core were histologically
related to swollen JCV-infected oligodendrocytes at the
advancing edge of the lesion [22, 23] surrounding a cen-
tral area [24] of demyelination with axonal loss. Taking
these findings into account, this unique rim and the core
pattern displayed on DWI could be of particular clinical
interest, as the presence of swollen oligodendrocytes at
the hyperintense edge is believed to represent ongoing
demyelination, and possibly a marker of active disease
[16], whereas the hypointense core corresponding to axo-
nal loss and increased extracellular space may identify
irreversibly damaged brain tissue [25].
The use of b-values higher than 1,000 s/mm2 increases
the diffusion-weighting power of DWI [26–28]. Based on
previous evidence from a single patient [29], we
hypothesised that DWI with a b-value of 3,000 s/mm2
(b3000) can improve the visualisation of the rim and core
of PML lesions compared to the standard DWI with a b-
value of 1,000 s/mm2 (b1000). In this retrospective study
we explore whether b3000 DWI provides a greater con-
trast of PML rim to normal-appearing white matter
(NAWM) and a different definition of the rim and the core
compared to b1000. Finally, we aimed to estimate the
contribution of T2 and diffusion effects to the DWI
Bhyperintense rim^ phenomenon by measuring the ADC
values of rim and core with both b-values.
Materials and methods
Study design and criteria
Imaging data from HIV-positive patients referred to UCLH
(University College London Hospitals) for brain MRI be-
tween 2004 and 2011 were retrospectively reviewed.
Inclusion criteria were: a definite diagnosis of PML in accor-
dance with the Consensus Statement from the AAN Neuro-
infectious Disease Section [11] (clinical and imaging findings
consistent with PML, confirmed by positive nucleic acid am-
plification of JCV-specific DNS in the CSF), positive HIV-
antibody status, and at least one brain MRI study performed
using b1000 and b3000 DWI sequences before the start of
cART. Patients with a PML ‘non-definite’ diagnosis (e.g. lack
of CSF virological confirmation) or with HIV-PML already
under treatment were excluded.
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Imaging data
I m a g i n g w a s p e r f o r m e d o n 1 . 5 - T s y s t e m s
(MAGNETOM® Symphony and Avanto, Siemens,
Erlangen, Germany) and included standard brain imaging
with sagittal and coronal spin echo T1-weighted images,
axial fast spin echo T2-weighted images and coronal
FLAIR images, as well as axial and coronal spin echo
T1-weighted images after gadolinium administration.
Axial trace-weighted DWI images with b-values of both
1,000 and 3,000 s/mm2 (TR range 3,200–3,900 and
3,200–4,400 ms for b1000 and b3000, respectively; TE
range 81–97 and 113–133 ms for b1000 and b3000, re-
spectively; matrix 128 × 128, field of view (FOV)
230 × 230 mm2, slice thickness 5 mm, gap 1.5 mm) were
acquired alongside b = 0 s/mm2 images with correspond-
ing parameters. The ADC maps generated automatically
by the manufacturer’s software were used.
Regions of interest
The rim and core of each PML lesion were identified and
manually outlined on consecutive axial slices of both b1000
and b3000 trace-weighted DWI, using FSLView with
standardised window settings (0–200 for b1000 DWI, 0–120
for b3000 DWI). All regions of interest (ROIs) were set in
consensus by two observers, initially drawn by a more junior
reader (8 years experience in neuroradiology), then reviewed
and confirmed by a more experienced reader (25 years expe-
rience in neuroradiology). The rim was identified as the bright
edge of the lesion, and the core as the central hypointense area
of each PML lesion. Rim and core were outlined on all the
slices in which they were visible, then automatically com-
bined to obtain rim and core volumes. Control ROIs were also
placed on each slice on subcortical normal-appearing white
matter (NAWM) in areas deemed to be unaffected on T2
and FLAIR images.
ROI signal intensities (SIs) were measured on b1000 and
b3000 DWI; the same ROIs generated with DWI trace-
weighted images were then superimposed on ADC maps to
get the corresponding ADC values. DWI rim and core SI
values were finally normalised to those of control ROIs to
obtain relative signal intensity ratios (SIRs).
Statistical methods
Statistical analyses were performed with GraphPad
PRISM Software, version 6.0 (La Jolla, CA, USA). The
Wilcoxon signed-rank test was used to compare values
between b1000 and b3000 datasets. P-values < 0.05 were
considered significant.
Results
Population
Seven patients with a definite diagnosis of PML (three fe-
males, four males, median age: 43 years, range: 19–66 years)
fulfilled the inclusion criteria. Patients’ demographics and
clinical details are provided in Table 1.
Five patients had a single white matter lesion, and the
remaining had two distinct lesions (patients #1 and #2). In
total, nine PML lesions were analysed: every one apart
from patient #6 was located in the supratentorial white
matter. All the lesions were hypointense on T1-weighted,
hyperintense on T2-weighted and FLAIR images, showed
no contrast enhancement, and displayed the typical rim-
core pattern with a peripheral rim of high signal and a
central area of low intensity on DWI.
The rim and core definition differs between b3000
and b1000 DWI
A similar delineation of PML lesions was obtained by b1000
and b3000 DWI, with comparable total volumes (b1000 DWI:
7.81 cm3, interquartile range (IQR) 4.69–29.43, vs. b3000
DWI: 8.87 cm3, IQR 4.38–25.34; p = 0.91; Fig. 1C).
However, the two b values significantly differed in
characterising components of PML lesions: in particular,
b3000 DWI provided significantly smaller rims than b1000
(3.44 cm3, IQR 2.51–8.16, vs. 5.62 cm3, IQR 4.40–15.66,
p = 0.004; Fig. 1A) and significantly bigger cores (4.77 cm3,
IQR 1.88–16.63 vs. 2.19 cm3, IQR 0.27–13.39, p = 0.004;
Fig. 1B). Thus, b1000 and b3000 DWI similarly identified
PML lesions, but resulted in a different characterisation of the
lesion components, with a more stringent delineation of the rim
with b3000 DWI (Fig. 2), and better delineation of the core on
both trace-weighted images and ADC maps (Figs. 2E and F).
The contrast between rim, core and NAWM is increased
with b3000 DWI
As expected with high b-values, SIs of the lesion rim (SIrim),
lesion core (SIcore) and NAWM (SINAWM) on b3000 were
lower than on b1000 trace-weighted DWI (Table 2). SIrim
was the highest on both b1000 and b3000 trace-weighted
DWI, followed by SINAWM and SIcore, respectively. Of note,
SIcore highly abated with b3000 DWI (Fig. 2).
The contrast (expressed by the SIR) between the lesion rim
and NAWM and between the lesion core and NAWM on
b3000 DWI was higher than on b1000 DWI images (SIR:
2.02, IQR 1.80–2.28 vs. 1.64, IQR 1.49–1.71, p = 0.004 and
0.68, IQR 0.57–0.79 vs. 0.98, IQR 0.71–1.17, p = 0.023, re-
spectively). Moreover, b3000 DWI strongly highlighted the
contrast between the rim and the core of PML lesions in
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comparison to b1000 DWI (SIR: 2.98, IQR 2.50–3.73 vs. 1.61
IQR 1.41–2.15, p = 0.008, Tables 2 and 3), with a particularly
evident signal drop in the core of b3000 (Fig. 2E). These data
clearly show that b3000 improves the contrast resolution be-
tween lesion rim, core and normal-appearing white matter,
facilitating the recognition of the rim-and-core pattern, which
is a hallmark of PML.
DWI hyperintense rim consists of regions with different
ADC values and b3000 excludes some high ADC areas
from the rim
Table 2 shows the ADC values of the lesion rim, lesion core
and NAWM on b1000 and b3000 DWI. As expected, b3000
resulted in lower ADC values and PML cores showed the
highest ADC with both b1000 and b3000.
On b1000 DWI, average ADC values of the lesion rim
were slightly higher than those of the NAWM (p = 0.022):
however, ADC values within the rim appeared to be hetero-
geneous, with definite foci of low ADC (Fig. 3, arrowheads).
We found all the spots with low ADC values identified on
b1000 were included within the rim on b3000 DWI (Fig. 3,
arrows), suggesting that themore stringent delineation of lesion
rim on b3000 resulted in the exclusion of some areas with
increased diffusion. Concordantly, average b3000 ADC values
of the rim were similar to NAWM (p = 0.129) (Table 2).
These data show that the hyperintense PML rim is a hetero-
geneous region, with a combination of components with reduced
and increased diffusion on both b1000 and b3000. Moreover,
delineation of the lesion rim with b3000 results in smaller areas,
excluding some components with increased diffusion.
Discussion
The American Academy of Neurology (AAN) Neuro-
infectious Disease Section recently stated that compatible im-
aging findings are one of the criteria required to establish a
non-invasive PML diagnosis [11]. However, subcortical white
matter T2-hyperintense and T1-hypointense signal alterations
are rather non-specific. Also post-contrast enhancement is of
little help, as it is present in other inflammatory and often
concomitant white matter diseases. On the other hand, an
asymmetrical ill-defined hyperintense DWI rim surrounding
Table 1 Demographics and clinical features of progressive multifocal leukoencephalopathy (PML) patients (n = 7)
Patient Gender Age, y Symptoms at diagnosis Location of the PML lesion Blood CD4+ lymphocytes
(absolute count with %)a
Plasma HIV
viral loadb
#1 M 49 Unknown 1. Right parietal 140 (11.7%) 25,400
2. Left occipito-parietal
#2 M 31 Right hemiparesis 1. Left fronto-parietal <10 (0%) 2,898,500
2. Right frontal
#3 F 19 Dysarthria, dysphagia, right-sided weakness Left fronto-temporal 50 (8.4%) 1,800
#4 F 34 Left hemiparesis Right fronto-parietal 70 50,000
#5 M 66 Progressive left hemiparesis Right frontal 290 (16.1%) 290,000
#6 M 44 Progressive cerebellar syndrome Left middle cerebellar peduncle 160 (14.5%) 425,300
#7 F 58 Dysphasia, right hemiparesis Left frontal 390 (10.2%) 250,000
M male, F female
a Cells/μl, normal range: 350–1,250
b Copies/ml
Fig. 1 b1000 and b3000 volumes (in mm3) of the rim and core of all
progressive multifocal leukoencephalopathy (PML) lesions are shown in
panels A and B, respectively. Overall, the rim volumes on b3000 were
lower, and the core volumes higher than their counterparts on b1000
diffusion-weighted imaging without any significant change in the total
lesion volume being noted (C)
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a hypointense core is a typical finding of full-blown PML
lesions, and, when detectable, allows a more confident inter-
pretation of otherwise nonspecific findings [18, 30].
In this study we found that b3000 improved the identification
of the typical PML rim-and-core pattern by increasing the con-
trast between rim, core and NAWM, with a particularly evident
signal drop within the core. The improvement was conspicuous
despite the expected loss of signal and consequent lower SNR
observed at high b-values [31, 32]. This is an important finding,
suggesting that the use of b3000may ultimately result in a higher
number of patients meeting the criteria for non-invasive diagno-
sis of PML. This could potentially allow a higher number of
patients to be diagnosed with PMLwithout necessarily requiring
invasive procedures, such as brain biopsy or JCV-positive CSF.
In selected cases it may also suggest the diagnosis of PML
despite a negative CSF, given the fact the JCV may initially be
absent in the CSF in a small percentage of PML cases.
The usefulness of DWI in the setting of PML is, however,
not only limited to diagnosis, as DWI can provide information
about brain structure and disease-related changes. High signal
regions on trace-DWI in PML lesions have been associated
with the advancing edge of oligodendrocyte infection [22],
whereas the hypointense core of older and larger lesions was
assumed to represent the irreversibly damaged brain tissue with
cellular debris [33]. Indeed, the role of PML DWI core as a
marker of disease-associated damage was confirmed by
Cosottini et al. [25], who found a significant correlation of
disease duration and severity with the core volume.
In our sample the PML core showed high ADC values in
both b1000 and b3000, consistently with an area of brain
tissue destruction and in agreement with other authors’ reports
[22, 25]. The PML rim showed average ADC values that were
slightly higher than NAWM in both b1000 and b3000, signi-
fying the bright DWI rim at least partly results from a T2
shine-through effect.
Despite average increased ADC values within the rim, in our
sample this was often heterogeneous, with some foci of low
ADC values in both b1000 and b3000, in agreement with other
reports [22, 23]. Of note, b3000 and b1000 DWI similarly
depicted the volume of PML lesions, but differed in the definition
of the rim and core subsets, with a smaller and more stringent
delineation of the rim in favour of a larger core volume with
b3000. In particular, b3000 DWI was found to exclude some
areas with normal to high ADC values from the rim, in keeping
with an increased diffusion-weighting power with high b-values.
This also resulted in averageADCvalues of the rim being similar
to the NAWM on b3000, instead of slightly higher than NAWM
as on b1000. It is thus logical to surmise that those regions that
Fig. 2 A representative patient is
shown in images A–F. On b1000
(B) and b3000 (E) trace-weighted
diffusion-weighted imaging,
progressive multifocal
leukoencephalopathy (PML) rim
is outlined in red, PML core in
blue, and normal-appearing white
matter (NAWM) in yellow and
green (A, D). Although similar
lesion volumes were identified by
the two b-values (sum of red and
blue components), the rim in
b1000 appeared thicker than in
b3000 (B,E); conversely, the core
in b3000 was more identifiable
and larger than in b1000, not only
on trace-weighted images (B, E)
but also on apparent diffusion
coefficient (ADC) maps (C, F)
Table 2 Signal intensity (SI) and apparent diffusion coefficient (ADC) values (×10-7 s/mm2) of progressive multifocal leukoencephalopathy (PML)
rim, normal-appearing white matter (NAWM) and PML core from b1000 and b3000 diffusion-weighted imaging datasets
b1000 SI b3000 SI b1000 ADC b3000 ADC
Rim 172.8 (162.2–187.5) 69.0 (60.2–77.8) 91.9 (78.3–97.6) 51.9 (45.1–56.6)
NAWM 109.8 (97.6–114.3) 33.1 (32.4–35.4) 74.6 (72.9–77.9) 49.6 (46.6–51.2)
Core 95.8 (76.2–125.3) 22.4 (18.8–26.2) 163.0 (152.5–186.4) 100.2 (90.0–105.6)
Values are expressed as median and interquartile ranges (25–75 percentiles)
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were reclassified by b3000 from rim into core correspond to
those with the highest ADC within the rim on b1000 imaging,
representing areas with a relatively more advanced infection
stage with cytolysis and debris accumulation. Therefore, b3000
DWI can reduce the heterogeneity of the rim by retaining only
the areas with the highest diffusion-weighted contribution and
thus with increased probability of active demyelination.
Identifying the portion of the rim expressing active demy-
elination, potentially responding to therapeutic measures,
from already damaged tissue is crucial information for clinical
decisions and for prognostic stratification. To prove
conclusively that the b3000 is more accurate than b1000 in
detecting a rim with active demyelination, one would require
histology from multiple biopsy sites of the rim, which is not
part of the current clinical practice in the management of
PML. Nevertheless, based on our data, it appears not unrea-
sonable to conjecture that DWI with a high b-value may pro-
vide more precise biomarkers of the areas with infectious ac-
tivity (i.e. the lesion rim) and irreversible brain damage (i.e.
the lesion core).
Themain limitations of this work are the retrospective nature
and the limited number of patients analysed. The sample size is
relatively small due to the relatively rarity of PML even in large
tertiary referral centres, but comparable to previous studies on
this topic (less than ten patients per study) [25, 33, 34]. In this
initial study with proof-of-concept purposes we used consensus
between two observers to outline the rim and core, but future
larger studies would certainly benefit from intra- and interob-
server variability assessment. Due to scanner variation and soft-
ware upgrades over time, there were some inevitable variations
in acquisition parameters between patients. To overcome this
limitation we decided to analyse the data by using relative mea-
sures (SIRs) within each patient, as this approach minimises the
effect of parameter variations between patients.
This study was conducted in HIV patients who were clin-
ically symptomatic and therefore had relatively sizeable PML
lesions. Future studies may need to look at the usefulness of
high b-value DWI for early PML detection in other patient
cohorts at risk, such as MS patients on natalizumab undergo-
ing routine surveillance imaging who are asymptomatic and
usually have smaller lesions [7, 8].
Conclusions
Our study shows that DWIwith a b-value of 3,000 s/mm2 allows
a more conspicuous depiction of the typical pattern of PML,
potentially increasing MRI accuracy for non-invasive PML di-
agnosis. Moreover, we showed that the DWI high-signal rim is
heterogeneous being composed of regions with different ADC
values, and that b3000 displays a thinner rim than b1000, ex-
cluding some areaswith highADCvalues, which are reclassified
into the core. Given the prognostic relevance of the rim and core
as a biomarker of disease activity and of tissue damage, respec-
tively, b3000 DWImay well be potentially useful to assess treat-
ment response, and to predict clinical outcomes in PML, which
will need to be further investigated in future prospective trials.
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